Biotech Stocks in “Total Eclipse” as Financial Pressures Mount
More than a year after biotech stock indices peaked, the markets are worse than ever.…
More than a year after biotech stock indices peaked, the markets are worse than ever.…
The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health…
The Dutch life sciences venture capital firm Forbion has bagged €185M in the first closing…
A Series B funding round has whipped up €40M for the Irish company Inflazome. This…
Update: The European venture capital firm Forbion closed fundraising for it's fourth life sciences fund…
Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for…
NorthSea Therapeutics has been founded in the Netherlands to develop a drug against NASH, a…
A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can…
Sander van Deventer is now a managing partner at Forbion after playing a critical role…
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor…
Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials…
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of…